LEXINGTON, Mass., Feb. 6, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ:
AGEN), an immuno-oncology company with an extensive pipeline of
agents designed to activate immune response to cancers, today
announced it will hold an Investor Day Thursday, February 20, 2020.
The Investor Day will present:
- Clinical data from pre-planned interim analyses of balstilimab
(anti-PD-1) and zalifrelimab (anti-CTLA-4);
- Clinical data from a dose-escalation study of AGEN1181, a novel
multi-functional T cell engager.
|
Date:
|
Thursday, February
20, 2020
|
|
|
|
Time:
|
9:00 –
11:00AM
|
|
|
|
Location:
|
New York,
NY (by invitation only)
|
|
|
|
Event details:
agenusbio.com
|
Presenters will include global experts in immune-oncology, Dr.
Chuck Drake, Co-Director, Cancer
Immunotherapy Program, Columbia
University Herbert Irving Comprehensive Cancer Center, and
Dr. Bradley Monk, M.D., FACS, FACOG,
Co‐Director of GOG Partners, Arizona Oncology (US Oncology Network)
and Professor, Gynecologic Oncology at University of Arizona, and Creighton University, Medical Director of US
Oncology Research Gynecology program in Phoenix, Arizona.
The event will be webcast live an may be accessed by visiting
the "Events & Presentations" page within the Investors section
of the Agenus website at www.agenusbio.com or by
using the link below. A replay of the webcast, as well as a
copy of the slide presentations that will be presented at the
event, will be available on the Agenus website following the
event.
Please note that in-person attendance is by invitation only
and advanced registration is required. If you are interested in
attending or for more information, please contact Regina Grebla, Agenus Investor Relations,
at investorrelations@agenusbio.com.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the
discovery and development of therapies that engage the body's
immune system to fight cancer. The Company's vision is to expand
the patient populations benefiting from cancer immunotherapy by
pursuing combination approaches that leverage a broad repertoire of
antibody therapeutics, proprietary cancer vaccine platforms, and
adoptive cell therapies (through its AgenTus Therapeutics
subsidiary). The Company is equipped with a suite of antibody
discovery platforms and a state-of-the-art GMP manufacturing
facility with the capacity to support early phase clinical
programs. Agenus is headquartered in Lexington, MA. For more information, please
visit www.agenusbio.com and our twitter handle @agenus_bio.
Information that may be important to investors will be routinely
posted on our website and twitter.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding the Company's plans
to release clinical data on balstilimab (anti-PD-1),
zalifrelimab (anti-CTLA-4) and AGEN1181 at an upcoming investor
day. These forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially.
These risks and uncertainties include, among others, the factors
described under the Risk Factors section of our most recent
Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed
with the Securities and Exchange Commission. Agenus cautions
investors not to place considerable reliance on the forward-looking
statements contained in this release. These statements speak only
as of the date of this press release, and Agenus undertakes no
obligation to update or revise the statements, other than to
the extent required by law. All forward-looking statements are
expressly qualified in their entirety by this cautionary
statement.
Contact:
Agenus Inc.
Regina Grebla, PhD
781-674-4495
Regina.Grebla@agenusbio.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/agenus-announces-investor-day-on-february-20-2020-301000608.html
SOURCE Agenus